News
ANI Pharmaceuticals Inc (ANIP) reports a robust quarter with significant revenue growth and upward revisions in 2025 guidance, driven by strong performance in rare disease and generics segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results